Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMoath AlbliwiKAKirti AroraFNFaris Naffa

Discussion

Loading...

Member takes

Overview

Retrospective analysis compares outcomes of CAR-T therapy in elderly patients with multiple myeloma and lymphomas, suggesting age alone shouldn't dictate therapy eligibility.

Key Points

  • This research aims to determine if age affects outcomes for patients receiving CAR-T therapy in blood cancers.
  • Retrospective cohort analysis of 105 healthcare organizations' data.
  • Patients aged 18–75 years and >75 years were included and grouped by age at CAR-T infusion.
  • Propensity score matching was used to balance characteristics between age groups.
  • Overall survival was 54.4% for 18–75 years vs. 49.0% for >75 years, not statistically significant.
  • ICU admissions were slightly higher in older patients, also not significant (18.8% vs. 14.3%).
  • Cytokine release syndrome rates were similar: 23.2% in younger vs. 25.9% in older patients.
  • Cytopenia incidence was comparable: 60.9% in younger vs. 59.3% in older patients.

Cite This Study

Albliwi et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db6dhttps://doi.org/10.1182/blood-2025-2773
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (<70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study2025
  2. 2Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis2025
  3. 3The influence of advanced age on outcomes in patients with diffuse large B-cell lymphoma treated with CAR-T therapy.2026
  4. 4CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.2026
  5. 5Anti‐<scp>CD19</scp> chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study2024 · 10 citations